title: [Clinical and economic benefits of the new antidiabetic drugs in the Czech Republic].
abstract: OBJECTIVE
  Description of efficiency, safety and cost-effectiveness of the therapy with new antidiabetics from the incretins group for the patients whose treatment with DPP4 inhibitors and GLP1 receptor agonists respectively, commenced based on the real data from the routine clinical practice in the Czech Republic.
  
  
  METHODS
  Collection of clinical data before the commencement of treatment and in the following 12 months. The following data was collected for all patients: demographic data, time elapsed from diagnosis, body weight, BMI, HbA1c, systolic and diastolic blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. After that a pharmaco-economic model was analyzed which can predict long-term incidence of microvascular and macrovascular complications, life span and a quality-adjusted life-year (QALY) span of life.
  
  
  RESULTS
  The data of 320 patients followed for 12 months was analyzed (255 treated with DPP4 inhibitors and 65 treated with GLP1 receptor agonists). The patients average age was 60.4/57.9 years and this innovative therapy was commenced for them after 9.1 years on average from their being diagnosed with diabetes. The initial glycated hemoglobin was higher (7.0%, or 7.6% HbA1c/IFCC). The previous therapy had been mainly based on metformin and on sulfonylurea derivatives. After 12 months of treatment statistically significant decreases were recorded in glycated hemoglobin (by 1.4% and 1.8% resp.), systolic blood pressure (by 4.7 mm Hg and 4.6 mm Hg resp.), diastolic blood pressure (by 1.8 mm Hg and 3.0 mm Hg resp.), LDL-cholesterol (by 0.3 mmol/l), triglycerides (by 0.4 mmol/l and 0.2 mmol/l resp.), body weight (by 1.6 kg and 4.5 kg resp.) and BMI (by 0.5 and 1.6 resp.). The pharmacoeconomic model predicted that the improvement of diabetes compensation in the group of DPP4 inhibitors would lead in one diabetic patient to life extension by 0.36 year and by 0.31 QALY, and in the group of GLP1 agonists by 0.45 year and by 0.39 QALY.
  
  
  CONCLUSIONS
  The analysis has shown that the treatment based on modern antidiabetic medications in the conditions of the Czech Republic reduces the incidence of microvascular and macrovascular complications, extends the life span and the standard quality (QALY) life span and, due to the prevented complications, also reduces health insurance spending.
authors.forename: Tomáš
authors.initials: T
authors.lastname: Doležal
authors.forename: Klára
authors.initials: K
authors.lastname: Kruntorádová
mesh_terms: D003362:Cost-Benefit Analysis; D018153:Czech Republic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D007004:Hypoglycemic Agents